(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Alector (ALEC) has an average outperform rating and a price target range of $6 to $41, according to analysts polled by Capital IQ. (MT Newswires covers...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Alector (ALEC) has an average rating of outperform and price targets ranging from $6 to $41, according to analysts polled by Capital IQ. (MT Newswires...
Alector (ALEC) has an average outperform rating and price target range of $6 to $54, according to analysts polled by Capital IQ. (MT Newswires covers...
Alector (ALEC) has an average rating of outperform and price targets ranging from $6 to $54, according to analysts polled by Capital IQ. (MT Newswires...
Alector (ALEC) said Tuesday that its first-in-human phase 1 study of AL101 for the potential treatment of neurodegenerative diseases, including Alzheimer's...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Alector (ALEC) said Monday that it has initiated the first-in-human phase 1 trial of AL044 to treat Alzheimer's Disease. The study is intended to...
Alector (ALEC) shares fell nearly 10.5% in Friday afternoon trading after Morgan Stanley downgraded the stock to equalweight from overweight and cut the...